Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
UPDATE: Eagle Pharmaceuticals (EGRX) Reports Q4 EPS of 48c
March 2, 2020 6:51 AM EST(Updated - March 2, 2020 6:52 AM EST)
Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.48 vs the analyst estimate of $0.49. Revenue for the quarter came in at $48.3 million versus the consensus estimate of $49.07 million.
2020 Expense Guidance
R&D spend in 2020, on a... More